Capricor Jumps as the FDA Agrees to Look at 24-Month Duchenne Data. Agreeing to Look Is Not Approving.

by Carter Whitfield · August 14, 2026

Equities Reporter, The SmallCap Signal

Capricor Therapeutics (Nasdaq: CAPR) was trading at $6.63, up $2.42 or 57.48%, at 1:02 p.m. ET on Friday, according to Stockanalysis.com, against a Thursday close of $4.21. It is a very large move that is also a long way off the session's high: the stock traded as high as $8.15 earlier in the day, and Reuters, in coverage carried by KFGO, reported it up 118% at $9.18 premarket. Volume by early afternoon was 55.5 million shares against 58.11 million outstanding. The session is unfinished and every figure here is intraday.

The catalyst came from the company's own second-quarter conference call on Thursday, not from an FDA announcement. Chief executive Linda Marbán told investors Capricor plans to file an amendment to its biologics license application for deramiocel, its cell therapy for Duchenne muscular dystrophy. BioSpace reported her saying: "FDA has indicated it is willing to review this amendment and upon receipt to extend the PDUFA action date accordingly."

Per BioSpace's account of the call, the amendment will contain 24-month open-label extension data from the Phase 3 HOPE-3 study "along with additional analyses on the existing data package in order to support a refined indication focused on the primary endpoint." The PDUFA target action date is August 22, 2026, and neither side has published a new one.

It is worth stating plainly what this is and is not. The FDA indicating it will review an amendment and extend its own clock is a procedural step — not an approval, not a commitment to approve, and not a signal about how the agency reads the data. The extension exists so reviewers have time, not because they have reached a conclusion. The review can still go against Capricor.

The setback the stock is climbing out of came on July 29, 2026, when an FDA advisory committee voted 9-3 that the company had not provided sufficient evidence of deramiocel's effectiveness in Duchenne muscular dystrophy. Benzinga reported that FDA staff raised concerns about post hoc changes to key analyses made after the trial concluded, and that the agency's briefing document said the data "does not provide substantial evidence of effectiveness" and that results "did not reach statistical significance and are, thus, difficult to interpret."

The market's verdict was immediate: Benzinga reported the shares down 52.36% to $3.13 on July 30, a 52-week low. Stockanalysis.com puts the 52-week range at $2.96 to $40.37. Reuters, via KFGO, said Friday's move still left the stock well below a $19.70 pre-setback level — so even after a 57% gain, the shares remain roughly two-thirds below where they traded before the panel met.

Marbán's framing has been that the committee was asked the wrong question. In Thursday's release she said, in a single continuous statement: "The Advisory Committee outcome was not the one we hoped for. The indication we requested in 2024 was the treatment of cardiomyopathy in DMD, and that is the question the Committee was asked to vote on, not the HOPE-3 primary endpoint. HOPE-3 was designed and powered to demonstrate efficacy in upper limb function; cardiac function was a key secondary endpoint, measured across all patients enrolled rather than only those with established cardiomyopathy. The full dataset has since been published in The Lancet following extensive and independent peer review, and we continue to believe there is a path to approval for Deramiocel." The middle sentence is the concession inside the defence: the cardiac evidence the panel judged came from a secondary endpoint measured across all enrolled patients, not from a trial built to answer the cardiomyopathy question. The release states the HOPE-3 primary endpoint of upper limb function, measured by PUL 2.0, achieved statistical significance at p=0.029.

The balance sheet is the part to read alongside the headline. Capricor reported cash, cash equivalents and marketable securities of $237,934,782 at June 30, 2026, down from $318.1 million at the end of 2025. The second-quarter net loss was $40,733,654, or $0.70 per share, against $25.9 million a year earlier. Research and development spending was $28.9 million and general and administrative expense $14.1 million, up from $5.7 million. Revenue was zero. The company said its resources fund operations for at least 12 months.

That is the risk profile in numbers: a clinical-stage company with no product revenue, burning roughly $40 million a quarter, capitalised at about $385 million intraday Friday. An advisory committee vote is not binding on the FDA, which cuts both ways — the agency is free to disregard the 9-3 recommendation and equally free to follow it. A company at this burn rate with one lead asset and a contested filing has an obvious incentive to raise capital, and dilution is a live risk however the review resolves.

The history is longer than one panel meeting: the FDA issued a complete response letter in July 2025 citing a lack of substantial evidence of effectiveness, according to NeurologyLive, then lifted it and accepted a Class 2 resubmission built on HOPE-3 data, setting the August 22 action date in March. What happens next is a filing, not a decision. Until the amendment is submitted and a new date published, August 22 remains the one on the books — and nothing said on Thursday's call changes what the agency will eventually conclude about the evidence.